Darolutamide (new indication: prostate cancer, metastatic and hormone-sensitive, in combination with docetaxel and androgen deprivation therapy)

Subject:

• Active Substance: Darolutamide
• Name: Nubeqa®
• Therapeutic area: Prostate cancer
• Pharmaceutical company: Bayer Vital GmbH

Time table:

• Start: 01.04.2023
• Final decision by G-BA: 21.09.2023

Final decision:

• Indication for a considerable additional benefit